Arbutus Biopharma (NASDAQ:ABUS) Given Buy Rating at Chardan Capital
Chardan Capital reissued their buy rating on shares of Arbutus Biopharma (NASDAQ:ABUS – Free Report) in a report issued on Wednesday, Benzinga reports. They currently have a $4.00 price objective on the biopharmaceutical company’s stock. A number of other brokerages have also recently issued reports on ABUS. HC Wainwright decreased their target price on Arbutus […]
More Stories
Top Miro Alternatives in 2026 | Free Competitors of Miro for Startups
Looking for an alternative to Miro? Don’t worry, I’ll share a list of tools that are better than Miro. This...
Malaysia & Indonesia Block Elon Musk’s Grok AI: Becomes the First Countries To Do So!
Malaysia and Indonesia become the first countries to block access to Elon Musk’s AI chatbot Grok, stating its misuse in...
What Documents Do You Need to Hire International Employees?
Hiring talent from abroad can move your business forward; however, paperwork decides how fast you move. You need clear records...
DOJ Inquiry Into Fed Chair: What to Know
By Andrew Moran The Federal Reserve was thrust into the spotlight on Jan. 11, after chair Jerome Powell said the...
Their Bodies Were Irreversibly Damaged, Now These Former Transgender Teens Are Fighting for Justice
By Darlene McCormick Sanchez Young people who used to identify as transgender have filed dozens of lawsuits in the past...
Hegseth Says Proposed $1.5 Trillion Military Budget Is ‘Message to the World’
By Ryan Morgan War Secretary Pete Hegseth on Jan. 12 said President Donald Trump’s call for a $1.5 trillion military...